ClinicalTrials.gg
Not yet recruitingNCT06396858ARCHIMEDESUpdated Oct 30, 2026

Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke

A Phase 4 interventional study of Rivaroxaban 2.5 Mg Oral Tablet and Colchicine 0.5 MG in Ischemic Stroke, sponsored by Brazilian Clinical Research Institute. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Brazilian Clinical Research Institute · Phase 4, Interventional, and Prevention

How we know

Updated Oct 30, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies testing rivaroxaban in Ischemic Stroke — 4 open to participants now, 4 under way, 2 of them phase 3. Rivaroxaban · Ischemic Stroke.

Planned enrollment
3rd of 10
4,500 · median 1,597
Started
2027
the only one that year
Phase 4
2 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Brazilian Clinical Research Institute

Among the 10 studies testing rivaroxaban in Ischemic Stroke, this one is the 3rd largest by planned enrollment, is the only one that started in 2027, is one of 2 in phase 4, and was the 8th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

4 of the 10 studies testing rivaroxaban in Ischemic Stroke are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rivaroxaban in Ischemic Stroke, or all of them as a file.
02

Study summary

The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial clinical trial, which will include at least 3000 and up to a maximum of 4500 patients with ischemic stroke without indication of oral anticoagulation.

Read the detailed description

In patients with ischemic stroke, within 14 days of symptom onset, to establish the efficacy and safety of two strategies in parallel: low-dose rivaroxaban and low-dose colchicine, compared with placebo.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • Stroke
  • Anticoagulation
  • rivaroxaban
  • colchicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with acute ischemic stroke aged ≥18 years old who, regardless of etiology and mechanism, do not have a definitive indication for anticoagulation, and whose symptoms onset has been within the last 14 days;
  • Receiving standard therapy for acute management of ischemic stroke;
  • For patients treated with fibrinolytics, a minimum period of 24 hours after the infusion of the lytic drug is required for randomization into the study.

Exclusion criteria

Exclusion Criteria:

  • Modified Rankin score of 4 or more at randomization;
  • Refusal to provide consent;
  • Severe renal failure, with (by CKD-EPI) estimated at \<15 mL/min/1.73 m2;
  • Severe liver failure (child C);
  • Indication for full-dose anticoagulation (for example, venous thromboembolism or atrial fibrillation);
  • Previous hemorrhagic stroke or history of intracranial hemorrhage;
  • Systemic treatment with a potent CYP 3A4 inhibitor (such as azole antifungals and protease inhibitors), or with a potent 3A4 inducer (such as rifampicin, phenytoin, phenobarbital, or carbamazepine);
  • History of inflammatory bowel disease or chronic diarrhea;
  • Prolonged treatment (> 1 month) with or systemic ;
  • History of recurrent pneumonia (3 or more hospitalizations in the last 12 months);
  • Pregnancy or breastfeeding;
  • Any other comorbidity other than stroke and CV disease (e.g., cancer) that, in the investigator's opinion, has a significant impact on the 12-month survival.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
4,500 participants (estimated)

Study arms

  • Active comparator
    Group 1

    rivaroxaban 2.5 mg Twice a day (BID) + colchicine 0.5 mg once daily (QD)

    Drug: Rivaroxaban 2.5 Mg Oral Tablet · Drug: Colchicine 0.5 MG

  • Active comparator
    Group 2

    rivaroxaban 2.5 mg BID + colchicine placebo QD

    Drug: Rivaroxaban 2.5 Mg Oral Tablet · Drug: Placebo Colchicine

  • Active comparator
    Group 3

    rivaroxaban placebo BID + colchicine 0.5 mg QD

    Drug: Colchicine 0.5 MG · Drug: Placebo Rivaroxaban

  • Placebo comparator
    Group 4

    rivaroxaban placebo BID + colchicine placebo QD

    Drug: Placebo Rivaroxaban · Drug: Placebo Colchicine

Interventions

  • DrugRivaroxabanStudies of RivaroxabanRivaroxaban pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

    Also known as: Xarelto

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.

    Also known as: Colchis

  • DrugPlacebo Rivaroxaban

    Patients will receive one tablet, per oral or orogastric route, twice a day, for a maximum of 12 months.

  • DrugPlacebo Colchicine

    Patients will receive one tablet, per oral or orogastric route, once a day, for a maximum of 12 months.

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint: Time to cardiovascular death, stroke, myocardial infarction (MI), or urgent arterial

    Time to cardiovascular death, stroke, myocardial infarction (MI), or urgent arterial revascularization

    Time frame: 12 months

  2. Primary safety endpoint (rivaroxaban versus placebo): Time to major bleeding according to the International Society of Thrombosis and Hemostasis classification

    Time to major bleeding according to the International Society of Thrombosis and Hemostasis classification

    Time frame: 12 months

  3. Primary safety endpoint (colchicine versus placebo): Hospitalization for respiratory infections

    Time to first hospitalization for respiratory infections

    Time frame: 12 months

Secondary outcomes

  1. Time to fatal or non-fatal stroke

    Time to fatal or non-fatal stroke

    Time frame: 12 months

  2. Time to CV death, MI, or stroke

    Time to CV death, MI, or stroke

    Time frame: 12 months

  3. Time to death from all causes, MI, or stroke

    Time to death from all causes, MI, or stroke

    Time frame: 12 months

  4. Time to fatal or non-fatal stroke, death, or transient ischemic attack

    Time to fatal or non-fatal stroke, death, or transient ischemic attack

    Time frame: 12 months

  5. Net clinical endpoint: time to CV death, MI, stroke, fatal bleeding, or critical site bleeding

    Time to CV death, MI, stroke, fatal bleeding, or critical site bleeding

    Time frame: 12 months

  6. Time to all-cause death

    Time to all-cause death

    Time frame: 12 months

Other outcomes

  1. modified Rankin score

    modified Rankin score as ordinal outcome

    Time frame: 12 months

  2. Venous thromboembolism

    Time to first venous thromboembolism

    Time frame: 12 months

  3. New-onset atrial fibrillation

    time to new-onset atrial fibrillation

    Time frame: 12 months

  4. Microvascular obstruction at head MRI (substudy)

    Microvascular obstruction at head MRI (substudy)

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 12 months is below that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Jul 2026 → Jan 2027, primary completion Aug 2027 → Jan 2028 and completion Dec 2027 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
May 2, 2024
StartEst.
Jan 2027was Jul 2026
Primary completionEst.
Jan 2028was Aug 2027
CompletionEst.
May 2028was Dec 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 2026→Jan 2027
Oct 30, 2026
Primary completion
Aug 2027→Jan 2028
Oct 30, 2026
Study completion
Dec 2027→May 2028
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Start date Jul 2026→Jan 2027
    Primary completion Aug 2027→Jan 2028
    Study completion Dec 2027→May 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06396858
Lead sponsor
Brazilian Clinical Research Institute
Collaborators
Alliança Diagnostic
Responsible party
Sponsor
First posted
May 2, 2024
Start date
Jan 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Remo Furtado, MD, PhD
Contact
remo.furtado@bcri.org.br
55 11 59047339
Renato D Lopes, MD, PhD
study chair · Brazilian Clinical Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rivaroxaban · Colchicine

Start the discussion